Home / Reports / AI in Healthcare 2026
Thank you for reading this post, don't forget to subscribe!
Clinical AI crossed from pilot to practice in 2026. 81% of U.S. physicians now use AI in their work — more than double the 38% recorded in 2023, according to the American Medical Association’s 2026 physician sentiment survey. That surge sits on top of a regulatory pipeline of more than 1,200 FDA-authorized AI devices and the first randomized trial evidence that AI can detect more cancers without more false alarms.
The regulatory pipeline keeps widening
The U.S. Food and Drug Administration’s AI-Enabled Medical Devices list reached 1,247 authorized devices in its July 2025 update, up from roughly 690 through 2023 — a near-doubling in two years. The pipeline remains heavily concentrated: an analysis of the FDA list found that about 76% of authorized AI devices are in radiology (image analysis across X-ray, CT and MRI), followed by cardiovascular and neurology at single-digit shares. This concentration means most clinical AI in real-world use today is diagnostic imaging software, not autonomous decision-making.
Clinicians have crossed the adoption threshold
The AMA’s 2026 survey shows physician AI use jumping to 81% from 38% in 2023, with the average number of use cases per physician rising to 2.3 from 1.1. The most common applications are summarizing medical research and drafting clinical documentation. Sentiment is warming in parallel: more than three-quarters of physicians now believe AI improves their ability to care for patients, up from 65% in 2023. Adoption is not unconditional — 85% of doctors want to be consulted on how AI is deployed, and 86% cite data privacy as essential to broader uptake.
Diagnostic accuracy: the MASAI evidence
The strongest outcome evidence comes from MASAI, a randomized controlled trial of more than 100,000 Swedish women published in The Lancet. AI-supported mammography reading detected 29% more cancers than standard reading — without an increase in false positives — and cut radiologists’ screen-reading workload by 44% (interim safety results, The Lancet Oncology, 2023). The additional cancers found were predominantly small, node-negative invasive tumors, and the full trial reported higher sensitivity with non-inferior interval-cancer and specificity rates. It is the first randomized evidence that AI assistance improves screening yield rather than merely matching human readers.
Drug discovery: strong Phase I, unproven Phase II
A 2024 analysis by Jayatunga and colleagues (Boston Consulting Group and the Wellcome Trust), published in Drug Discovery Today, found that 21 of 24 AI-discovered molecules that had completed Phase I trials succeeded — roughly an 87% pass rate, well above the historical industry norm of 40–65%. The advantage narrows sharply later: Phase II success for AI-derived molecules was about 40%, in line with conventional drugs, where efficacy rather than safety is the bar. The takeaway is that AI is demonstrably good at generating drug-like, well-tolerated molecules, but has not yet proven it can improve the odds that a drug actually works.
Documented outcomes: giving clinicians time back
Beyond diagnosis, the clearest measured benefit is administrative. In a deployment across The Permanente Medical Group, 7,260 Kaiser Permanente physicians used ambient AI scribes across more than 2.5 million patient encounters between late 2023 and 2024, saving an estimated 15,791 hours of documentation time. In the accompanying evaluation, 82% of physicians said their overall work satisfaction improved and 84% reported a positive effect on patient communication — a rare large-scale, real-world signal that AI can address clinician burnout.
Market momentum meets a trust gap
Grand View Research valued the global AI-in-healthcare market at $36.7 billion in 2025 and projects it will reach $505.6 billion by 2033, a 38.9% compound annual growth rate; Precedence Research puts the 2025 figure at a comparable $36.96 billion. Investment is following: U.S. digital-health startups raised $14.2 billion in 2025 (Rock Health), the strongest year since 2022, with AI-labeled companies capturing 54% of all funding, up from 37% a year earlier. Yet patient confidence lags — a Pew Research Center survey found 60% of U.S. adults would be uncomfortable if their provider relied on AI to diagnose and treat them, a reminder that adoption inside the clinic is outpacing trust outside it.
Frequently asked questions
How many AI medical devices has the FDA authorized?
More than 1,200 — the FDA’s AI-Enabled Medical Devices list reached 1,247 authorizations in its July 2025 update, up from about 690 through 2023. Roughly 76% are radiology/imaging devices.
What share of physicians use AI?
81% of U.S. physicians reported using AI in the AMA’s 2026 survey, more than double the 38% recorded in 2023, with an average of 2.3 use cases each.
Does AI actually improve cancer detection?
In the randomized MASAI trial published in The Lancet, AI-supported mammography detected 29% more cancers with no rise in false positives, while cutting radiologist reading workload by 44%.
Sources
- U.S. FDA, Artificial Intelligence-Enabled Medical Devices (list), 2025 — https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices
- IntuitionLabs, FDA’s AI Medical Device List: Stats, Trends & Regulation, 2025 — https://intuitionlabs.ai/articles/fda-ai-medical-device-tracker
- American Medical Association, AI usage among doctors doubles as confidence in technology grows, March 2026 — https://www.ama-assn.org/press-center/ama-press-releases/ama-ai-usage-among-doctors-doubles-confidence-technology-grows
- The Lancet, MASAI trial — interval cancer, sensitivity and specificity of AI-supported mammography screening, 2025 — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02464-X/abstract
- Jayatunga et al., How successful are AI-discovered drugs in clinical trials? (Drug Discovery Today, BCG/Wellcome), 2024 — https://www.sciencedirect.com/science/article/pii/S135964462400134X
- Kaiser Permanente / The Permanente Medical Group, ambient AI scribe deployment study, 2024 — https://www.epocrates.com/online/article/kaiser-permanente-study-suggests-ambient-ai-may-alleviate-physician-burnout
- Grand View Research, Artificial Intelligence In Healthcare Market Report, 2025 — https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market
- Precedence Research, Artificial Intelligence in Healthcare Market, 2025 — https://www.precedenceresearch.com/artificial-intelligence-in-healthcare-market
- Rock Health, 2025 Year-End Digital Health Funding Overview, 2026 — https://rockhealth.com/insights/2025-year-end-digital-health-funding-overview-a-tale-of-two-markets/
- Pew Research Center, 60% of Americans Would Be Uncomfortable With Provider Relying on AI in Their Own Health Care, 2023 — https://www.pewresearch.org/science/2023/02/22/60-of-americans-would-be-uncomfortable-with-provider-relying-on-ai-in-their-own-health-care/